Back to top

Analyst Blog

Dr. Reddy’s Laboratories (RDY - Analyst Report) recently announced the launch of its generic version of Merck & Co’s (MRK - Analyst Report) Singulair oral granules (montelukast) following the receipt of US Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA).

Dr. Reddy’s launched its generic version of Singulair oral granules in 4 mg dosage in the US on September 26, 2012.

According to IMS Health, US branded sales of Singulair oral granules were approximately $61 million for the twelve months ended July 30, 2012. We note Singulair lost patent exclusivity in the US in August 2012.

Dr Reddy’s had launched its generic version of Singulair tablets (10 mg) and chewable tablets (4 mg & 5 mg) in the US on August 6, 2012.

Dr. Reddy’s had quite a few generic launches this year. On September 17, 2012, it launched its generic version of GlaxoSmithKline’s (GSK - Analyst Report) Amoxil (amoxicillin) tablets (500 mg and 875 mg), capsules (250 mg and 500 mg) and oral suspension (125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, and 400 mg/5 ml) in the US.

Other recent launches include Dr. Reddy’s generic version of Pfizer Inc.’s (PFE - Analyst Report) cholesterol drug, Lipitor, Roche Holdings Ltd.’s (RHHBY - Analyst Report) Boniva, Glaxo’s Requip and Novartis AG’s (NVS - Analyst Report) over-the-counter (OTC) drug, Prevacid.

Our Recommendation

We currently have a Neutral recommendation on Dr. Reddy’s. The stock carries a Zacks #3 Rank (“Hold” rating) in the short run. We believe that generic launches will continue to drive revenues at Dr. Reddy’s Global Generics segment, which climbed 32% to $343 million in the first quarter of fiscal 2012.

Primary contribution came from both North America and Russia and other CIS (Commonwealth of Independent States) markets (up 38% y/y) followed by India (up 19% y/y) and Europe (up 14% y/y). Growth was mainly driven by new generic launches and an increase in the market share of existing key products.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%